Drugs / NGGT006
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06293729 | Jun 2024 → Mar 2025 overdue | familial hypercholesterolemia | Suzhou Municipal Hospital | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06125847 | Oct 2023 → Nov 2024 overdue | homozygous familial hypercholesterolemia | First Affiliated Hospital Xi'an Jiaotong University | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NGGT006 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06293729 ↗ |
| Action | Restore | “carrying codon-optimized human LDLR gene, driving the expression of LDLR protein with normal function” NCT06125847 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “NGGT006 uses adeno-associated virus (AAV) as a vector” NCT06293729 ↗ |
| Route | Intravenous | “Single intravenous infusion of NGGT006” NCT06125847 ↗ |
| Target | LDLR | “NGGT006 is an adeno-associated viral (AAV) vector carrying codon-optimized human LDLR gene” NCT06125847 ↗ |